Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Journal
The Lancet
Journal Volume
394
Journal Issue
10198
Pages
576-586
Date Issued
2019
Author(s)
Reich K.
Gooderham M.
Tha?i D.
Crowley J.J.
Ryan C.
Krueger J.G.
Flack M.
Gu Y.
Williams D.A.
Thompson E.H.Z.
Paul C.
SDGs
Publisher
Lancet Publishing Group
Type
journal article